Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral Factor XIIa inhibitor
- Development stage
- Preclinical
- Lead developer
- KalVista Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KalVista Pharmaceuticals is developing an oral Factor XIIa inhibitor program, which consists of a portfolio of structurally diverse small molecules designed to potently and selectively inhibit both the Factor XII (FXII) zymogen and its activated form (FXIIa). By targeting FXIIa, these candidates aim to suppress the initiation and amplification of the kallikrein-kinin system (KKS) activation. This mechanism is being explored for the prophylaxis of Hereditary Angioedema (HAE) and the prevention of thrombosis with a potentially lower bleeding risk than traditional anticoagulants. Furthermore, the program targets chronic inflammatory and fibrotic vascular diseases where FXIIa and the KKS are implicated, such as diabetic macular edema (DME), idiopathic pulmonary fibrosis (IPF), and neuroinflammation. The program is currently in the preclinical stage of development.
- Other names
- Factor XIIa inhibitorFXIIa inhibitororal FXIIa inhibitor
02
Targets
FXIIa (Coagulation Factor XIIa)
Beyond the preview
Go deeper on oral Factor XIIa inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral Factor XIIa inhibitor.